EVOQ's technology platform utilizes a proprietary NanoDisc that has been optimized to deliver antigens to restore immune tolerance.

In January 2023, EVOQ announced a collaboration and licensing agreement with US biotech Gilead Sciences , to advance its proprietary technology for the treatment of rheumatoid arthritis and lupus.